secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001193125-26-130383
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences reports 2025 net loss $106.2M; Phase 3 CoMpass enrollment to complete mid-2026
--------------------------------------------------------------------------------

- Cash and equivalents $144.2M as of Dec 31, 2025; sufficient to fund operations into Q1 2027.
- Phase 3 CoMpass trial enrollment completion expected by mid-2026; topline data in 2H 2027.
- Phase 1b/2 NMIBC trial initial 3-month clinical data on track for mid-2026.
- New formulation for non-ocular solid tumors achieved 12-month stability; patent filed for coverage into 2046.
- Net loss for 2025 was $106.2M vs $86.9M in 2024; R&D expenses increased to $90.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312526130383/0001193125-26-130383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312526130383/aura-20260330.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-130383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer